argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025

Rhea-AI Summary

argenx (Nasdaq: ARGX) announced an upcoming R&D webinar focusing on their ARGX-119 program, scheduled for September 16, 2025, at 2:00pm ET. The event, titled "R&D Spotlight | Pioneering MuSK Biology with ARGX-119," marks the first in a mini-series highlighting the company's pipeline and R&D strategy.

The webinar will feature argenx management, scientific leadership, and key opinion leaders discussing the MuSK agonist program and its potential applications in treating neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA). The presentation will be accessible through the company's investor relations website.

August 19, 2025

Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced it will host a webinar, titled “R&D Spotlight | Pioneering MuSK Biology with ARGX-119” on Tuesday, September 16, 2025, at 2:00pm ET.

The webinar will be the first of a ‘mini’ series highlighting the argenx pipeline and research and development strategy. argenx management and scientific leadership will be joined by key opinion leaders, who will discuss the development of the MuSK agonist program, ARGX-119, and its potential to treat neuromuscular diseases, including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA).

A webcast of the event can be accessed on the Investors section of the argenx website at argenx.com/investors. A replay of the webcast will be available on the argenx website for approximately one year following the presentation.

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

Contacts

Media:

Colin McBean
cmcbean@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

FAQ

When is argenx (ARGX) hosting its R&D webinar on ARGX-119?

argenx will host the R&D webinar on Tuesday, September 16, 2025, at 2:00pm ET.

What diseases will ARGX-119 target according to argenx's webinar announcement?

ARGX-119 aims to treat neuromuscular diseases including congenital myasthenic syndromes (CMS), amyotrophic lateral sclerosis (ALS), and spinal muscular atrophy (SMA).

How can investors access argenx's ARGX-119 R&D webinar?

Investors can access the webinar through the Investors section of argenx's website at argenx.com/investors. A replay will be available for approximately one year.

What is the focus of argenx's ARGX-119 program?

ARGX-119 is a MuSK agonist program being developed for the treatment of various neuromuscular diseases.